Part 2
Immunology of multiple sclerosis
CoI: These videos were sponsored by Merck and for regulatory purposes this has to be disclosed. However, this was collaborative and the content was generated by a video production company following generation of a story board created by them and importantly ProfK and B and BartsMS PPI members acting as consultants via Queen Mary University of London.
Iron Rims image from Frontiers The characteristic feature of is multi-focal inflammatory activity; an infiltration of immune cells leading to loss of myelin and axons within these areas creating the appearance of round lesions. The natural evolution of these lesions like any area of injury in the rest of the body and shrink to a certain degree overtime. A fraction, however, continue to smoulder...
As part so the “can”-“ing town” film festival ProfK has been nominated for an “EnRee” for best animated short. During the COVID pandemic we have made these movies. They are about 5 minutes long. These are five short animated clips that we hope will educate you as: doctors, nurses, people with MS and general public They are about MS, the immune system, the...
Nourbakhsh et al. have the honour of publishing the first article of 2021 that will change my practice. As bright and shiny as all the monoclonal antibodies on our treatment shelf are compared to the dusty and lacklustre drugs used to treat the symptoms of MS. However, the symptomatic treatments determine day-to-day life for many pwMS: fatigue, spasms, neuropathic pain, etc. For fatigue, the most...
In the COVID era the movie and cinema industry has taken a bit of a beating. You may have heard of Cannes and the Oscars In the East end of London the Canning Town‘ film festival is on and ProfK has been nominated for an “En-ree” (after Henry Croft) An En-ree Category: Best Animated Shorts We will be premiering them from Tomorrow CoI: This event was sponsored by Merck. But ProfK...
After rejection from the Lancet doi:SSRN ID3631244, this COVID paper Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.Sormani et al.Ann Neurol. 2021. doi: 10.1002/ana.26028. arrives in the Anals of Neurology. This is about 7 months later, when I guess people don’t really care much any more.. The media may pick it up, but there is now data from the global registires...
I bang on about this subject, over and over and over again about treatment failures. Animal studies are not the main reason for failure. It is trial design. This is the biggest threat. I am sorry to say that sometimes I get a pat on the head by the neuros and and get sent to the corner to shut-up. They say “You will respect my authority”..Now piss off! We are planning on doing trials...
You asked “However, some subsets of pro-inflammatory B-cells were increased, indicating that some B-cells can “promptly arise” after Ocrevus treatment and that “anti-CD20 treatment does not reconstitute a fully healthy immune system or re-establish immune tolerance in all patients, supporting the need for retreatment,” the team wrote. An explanation? The study showed what would be expected...
Bookmark this page you may want it. Are you worried that you have been exposed to someone carrying coronavirus? Why not consider taking part in a COVID-19 prevention clinical trial? If you think your job or living circumstances has exposed you to someone who has tested positive for coronavirus, you may be able to take part in a COVID-19 clinical research study. You will have access to no-cost...
There is some concern that the effectiveness of the BioNTect vaccine based on news coming out of Israel. The UK took the rather, in my opinion, mad decision to extend the second dose from 3 to 12 weeks for the Pfizer vaccine to make it more like the Astrazeneca /Oxford vaccine. So now we need to know how much protecion you get from one Jab of vaccine But the stats on the News from Israel suggests...